

## Marina Bozilenko resigns from Board of Directors of SynAct Pharma

**SynAct Pharma AB (publ) ("SynAct") announced today Marina Bozilenko has notified the Board of her resignation as member of the Board of Directors due to personal reasons.**

"We are grateful for Marina's time and effort serving on the Board. She has been a valuable asset to SynAct. We wish her the best of luck," said SynAct Chairman Uli Hacksell.

"I very much enjoyed working with the management team and Board of Directors of SynAct, but unfortunately my personal and professional commitments have increased a great deal and I am no longer able to contribute adequate time and effort to SynAct. I resign my position with regret and wish the company and everyone involved a productive and successful future," said Marina Bozilenko.

**For further information, please contact:**

**Uli Hacksell**

Chairman, SynAct Pharma AB

Email: [investor.relations@synactpharma.com](mailto:investor.relations@synactpharma.com)

**About SynAct Pharma AB**

SynAct Pharma AB (Nasdaq Stockholm: SYNACT) is a clinical stage biotechnology company focused on the resolution of inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation resolution activity to help patients achieve immune balance and overcome their inflammation. For more information: [www.synactpharma.com](http://www.synactpharma.com).

**Attachments**

[Marina Bozilenko resigns from Board of Directors of SynAct Pharma](#)